Albumin-based nanoparticles: a promising strategy to overcome cancer drug resistance

Abstract

Circumvention of cancer drug resistance is one of the major investigations in nanomedicine. In this regard, nanotechnology-based drug delivery has offered various implications. However, protein-based nanocarriers have been a versatile choice compared to other nanomaterials, provided by their favorable characteristics and safety profiles. Specifically, albumin-based nanoparticles have been demonstrated to be an effective drug delivery system, owing to the inherent targeting modalities of albumin, through gp60- and SPARC-mediated receptor endocytosis. Furthermore, surface functionalization was exploited for active targeting, due to albumin’s abundance of carboxylic and amino groups. Stimuli-responsive drug release has also been pertained to albumin nano-systems. Therefore, albumin-based nanocarriers could potentially overcome cancer drug resistance through bypassing drug efflux, enhancing drug uptake, and improving tumor accumulation. Moreover, albumin nanocarriers improve the stability of various therapeutic cargos, for instance, nucleic acids, which allows their systemic administration. This review highlights the recent applications of albumin nanoparticles to overcome cancer drug resistance, the nano-fabrication techniques, as well as future perspectives and challenges.

Keywords

Albumin / active targeting / cancer therapy / drug delivery / multi-drug resistance / nanoparticles / stimuli- response release / nucleic acid therapy

References

[1] Falzone L,Libra M.Evolution of cancer pharmacological treatments at the turn of the third millennium..Front Pharmacol2018;9:1300 PMCID:PMC6243123

[2] Schirrmacher V.From chemotherapy to biological therapy: a review of novel concepts to reduce the side effects of systemic cancer treatment (Review)..Int J Oncol2019;54:407-19 PMCID:PMC6317661

[3] Mansoori B,Davudian S.The different mechanisms of cancer drug resistance: a brief review..Adv Pharm Bull2017;7:339-48 PMCID:PMC5651054

[4] Wang X,Chen X.Drug resistance and combating drug resistance in cancer..Cancer Drug Resist2019;2:141-60

[5] Nounou MI,Ahmed N.Breast cancer: conventional diagnosis and treatment modalities and recent patents and technologies..Breast Cancer (Auckl)2015;9:17-34 PMCID:PMC4589089

[6] Housman G,Heerboth S.Drug resistance in cancer: an overview..Cancers (Basel)2014;6:1769-92 PMCID:PMC4190567

[7] Schneider B,Krippner-Heidenreich A.Potent antitumoral activity of TRAIL through generation of tumor-targeted single-chain fusion proteins..Cell Death Dis2010;1:e68 PMCID:PMC3032523

[8] Szakács G,Ludwig JA.Targeting multidrug resistance in cancer..Na rev Drug discov2006;5:219-34

[9] Allen TM.Ligand-targeted therapeutics in anticancer therapy..Nat Rev Cancer2002;2:750-63

[10] Lee ES,Kim D.Tumor pH-responsive flower-like micelles of poly(L-lactic acid)-b-poly(ethylene glycol)-b-poly(L-histidine)..J Control Release2007;123:19-26 PMCID:PMC2196406

[11] Kim D,Lee ES.In vivo evaluation of doxorubicin-loaded polymeric micelles targeting folate receptors and early endosomal pH in drug-resistant ovarian cancer..Mol Pharm2009;6:1353-62 PMCID:PMC2760434

[12] Palmer AC.Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy..Cell2017;171:1678-91.e13 PMCID:PMC5741091

[13] Leary M,Lapinska K.Sensitization of drug resistant cancer cells: a matter of combination therapy..Cancers (Basel)2018;10:483 PMCID:PMC6315347

[14] Zhang M,Cui Y.Nanotechnology-based combination therapy for overcoming multidrug-resistant cancer..Cancer Biol Med2017;14:212-27 PMCID:PMC5570599

[15] Da Silva CG,Ossendorp F.The potential of multi-compound nanoparticles to bypass drug resistance in cancer..Cancer Chemother Pharmacol2017;80:881-94 PMCID:PMC5676819

[16] Yuan Y,Xia X.Nanoparticle delivery of anticancer drugs overcomes multidrug resistance in breast cancer..Drug Delivery2016;23:3350-7

[17] Verma D,Kaul S.Protein based nanostructures for drug delivery..J Pharm (Cairo)2018;2018:9285854 PMCID:PMC5976961

[18] Mao SJ,He R.Uptake of albumin nanoparticle surface modified with glycyrrhizin by primary cultured rat hepatocytes..World J Gastroenterol2005;11:3075-9 PMCID:PMC4305843

[19] Kremer P,Sinn H.Laser-induced fluorescence detection of malignant gliomas using fluorescein-labeled serum albumin: experimental and preliminary clinical results..Neurological Research2000;22:481-9

[20] Parodi A,Soond SM.Albumin nanovectors in cancer therapy and imaging..Biomolecules2019;9:218 PMCID:PMC6627831

[21] Maeda H,Sawa T.Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review..J Control Release2000;65:271-84

[22] Rempel SA,Gutiérrez JA.SPARC: a potential diagnostic marker of invasive meningiomas..Clin Cancer Res1999;5:237-41

[23] Hirose M,Tanabe T.Recombinant human serum albumin hydrogel as a novel drug delivery vehicle..Mat Sci Eng C2010;30:664-9

[24] Elzoghby AO,Elgindy NA.Albumin-based nanoparticles as potential controlled release drug delivery systems..J Control Release2012;157:168-82

[25] Hu YJ,Sun TQ.Binding of anti-inflammatory drug cromolyn sodium to bovine serum albumin..Int J Biol Macromol2006;39:280-5

[26] Tantra R,Quincey P.Characterisation of the de-agglomeration effects of bovine serum albumin on nanoparticles in aqueous suspension..Colloids Surf B Biointerfaces2010;75:275-81

[27] Kratz F.A clinical update of using albumin as a drug vehicle - a commentary..J Control Release2014;190:331-6

[28] Elzoghby AO,Kamel NM.Implications of protein- and Peptide-based nanoparticles as potential vehicles for anticancer drugs..Adv Protein Chem Struct Biol2015;98:169-221

[29] Lee ES.Albumin-based potential drugs: focus on half-life extension and nanoparticle preparation..J Pharm Investig2016;46:305-15

[30] Vaz J,Sasor A.SPARC: a potential prognostic and therapeutic target in pancreatic cancer..Pancreas2015;44:1024-35 PMCID:PMC4568900

[31] An FF.Strategies for preparing albumin-based nanoparticles for multifunctional bioimaging and drug delivery..Theranostics2017;7:3667-89 PMCID:PMC5667340

[32] Son S,Lee SJ.Self-crosslinked human serum albumin nanocarriers for systemic delivery of polymerized siRNA to tumors..Biomaterials2013;34:9475-85

[33] Gaca S,Rodel C.Survivin-miRNA-loaded nanoparticles as auxiliary tools for radiation therapy: preparation, characterisation, drug release, cytotoxicity and therapeutic effect on colorectal cancer cells..J Microencapsul2012;29:685-94

[34] Langer K,Vogel V.Optimization of the preparation process for human serum albumin (HSA) nanoparticles..Int J Pharmaceut2003;257:169-80

[35] Weber C,Kreuter J.Desolvation process and surface characterisation of protein nanoparticles..Int J Pharm2000;194:91-102

[36] Gong J,Zhou J.Synthesis, characterization, drug-loading capacity and safety of novel octyl modified serum albumin micelles..Int J Pharm2009;376:161-8

[37] Bae S,Kim TH.Doxorubicin-loaded human serum albumin nanoparticles surface-modified with TNF-related apoptosis-inducing ligand and transferrin for targeting multiple tumor types..Biomaterials2012;33:1536-46

[38] Yu S,Jiang M.Nanogels prepared by self-assembly of oppositely charged globular proteins..Biopolymers2006;83:148-58

[39] Qi J,He F.Nanoparticles with dextran/chitosan shell and BSA/chitosan core--doxorubicin loading and delivery..Int J Pharm2010;393:176-84

[40] Bronich TK,Shlyakhtenko LS.Polymer micelle with cross-linked ionic core..J Am Chem Soc2005;127:8236-7

[41] Lu YL,Feng C.Co-delivery of cyclopamine and doxorubicin mediated by bovine serum albumin nanoparticles reverses doxorubicin resistance in breast cancer by down-regulating P-glycoprotein Expression..J Cancer2019;10:2357-68 PMCID:PMC6584414

[42] Xu R,Juliano RL.Targeted albumin-based nanoparticles for delivery of amphipathic drugs..Bioconjugate Chem2011;22:870-8 PMCID:PMC3129787

[43] Choi SH,Choi JS.Inhalable self-assembled albumin nanoparticles for treating drug-resistant lung cancer..J Controll Release2015;197:199-207

[44] Hassanin IA.Self-assembled non-covalent protein-drug nanoparticles: an emerging delivery platform for anti-cancer drugs..Expert Opin Drug Del2020;4:1-22

[45] Liu L,Zhou M.Biomimetic human serum albumin nanoparticle for efficiently targeting therapy to metastatic breast cancers..ACS Appl Mater Interfaces2017;9:7424-35

[46] Fu Q,Zhang W.Nanoparticle albumin-bound (NAB) technology is a promising method for anti-cancer drug delivery..Recent Pat Anticancer Drug Discov2009;4:262-72

[47] Cortes J.Nanoparticle albumin-bound (nab™)-paclitaxel: improving efficacy and tolerability by targeted drug delivery in metastatic breast cancer..Eur J Cancer Suppl2010;8:1-10

[48] Gelderblom H,Nooter K.Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation..Eur J Cancer Suppl2001;37:1590-8

[49] Desai N,Yao Z.Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel..Clin Cancer Res2006;12:1317-24

[50] Yu X,Xie C.An in vitro and in vivo study of gemcitabine-loaded albumin nanoparticles in a pancreatic cancer cell line..Int J Nanomed2015;10:6825-34 PMCID:PMC4636168

[51] Tang Y,Wu A.Co-delivery of trichosanthin and albendazole by nano-self-assembly for overcoming tumor multidrug-resistance and metastasis..ACS Appl Mater Interfaces2017;9:26648-64

[52] Kim B,Park S.Albumin nanoparticles with synergistic antitumor efficacy against metastatic lung cancers..Colloids Surf B Biointerfaces2017;158:157-66

[53] Desale JP,Kushwah V.Chemosensitizer and docetaxel-loaded albumin nanoparticle: overcoming drug resistance and improving therapeutic efficacy..Nanomedicine (London)2018;13:2759-76

[54] Tang B,Gou Y.VE-albumin core-shell nanoparticles for paclitaxel delivery to treat MDR breast cancer..Molecules2018;23:2760 PMCID:PMC6278303

[55] Motevalli SM,Liu L.Co-encapsulation of curcumin and doxorubicin in albumin nanoparticles blocks the adaptive treatment tolerance of cancer cells..Biophys Rep2019;5:19-30

[56] Fang J,Yang G.Albumin-MnO2 gated hollow mesoporous silica nanosystem for modulating tumor hypoxia and synergetic therapy of cervical carcinoma..Colloids Surf B Biointerfaces2019;179:250-9

[57] Zhao P,Wu A.Dual-targeting to cancer cells and M2 macrophages via biomimetic delivery of mannosylated albumin nanoparticles for drug-resistant cancer therapy..Adv Funct Mater2017;27:

[58] Kayani Z,Bordbar AK.Doughnut-shaped bovine serum albumin nanoparticles loaded with doxorubicin for overcoming multidrug-resistant in cancer cells..Int J Biol Macromol2018;107:1835-43

[59] Onafuye H,Mulac D.Doxorubicin-loaded human serum albumin nanoparticles overcome transporter-mediated drug resistance in drug-adapted cancer cells..Beilstein J Nanotechnol2019;10:1707-15 PMCID:PMC6720578

[60] Gad SF,Park JE.Enhancing docetaxel delivery to multidrug-resistant cancer cells with albumin-coated nanocrystals..Mol Pharm2018; PMCID:PMC6064681

[61] Lian H,Hu Y.Self-assembled albumin nanoparticles for combination therapy in prostate cancer..Int J Nanomedicine2017;12:7777-87 PMCID:PMC5661507

[62] Chen Q,Liang C.Drug-induced co-assembly of albumin/catalase as smart nano-theranostics for deep intra-tumoral penetration, hypoxia relieve, and synergistic combination therapy..J Control Release2017;263:79-89

[63] Guo Z,Di Y.Antitumor effect of gemcitabine-loaded albumin nanoparticle on gemcitabine-resistant pancreatic cancer induced by low hENT1 expression..Int J Nanomedicine2018;13:4869-80 PMCID:PMC6122898

[64] Dvorak P,Mohelnikova-Duchonova B.Downregulation of ABC transporters in non-neoplastic tissues confers better prognosis for pancreatic and colorectal cancer patients..J Cancer2017;8:1959-71 PMCID:PMC5559956

[65] Zhou L,Li Y.Stimuli-responsive nanomedicines for overcoming cancer multidrug resistance..Theranostics2018;8:1059-74 PMCID:PMC5817110

[66] Taipale J,Cooper MK.Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine..Nature2000;406:1005-9

[67] Liu M,Tang W.Isocyclopamine, a novel synthetic derivative of cyclopamine, reverts doxorubicin resistance in MCF-7/ADR cells by increasing intracellular doxorubicin accumulation and downregulating breast cancer stem-like cells..Tumor Biol2016;37:1919-31

[68] Ji RC.Hypoxia and lymphangiogenesis in tumor microenvironment and metastasis..Cancer Lett2014;346:6-16

[69] Hu YL,Jahangiri A.Hypoxia-induced autophagy promotes tumor cell survival and adaptation to antiangiogenic treatment in glioblastoma..Cancer Res2012;72:1773-83 PMCID:PMC3319869

[70] Semenza GL.Targeting HIF-1 for cancer therapy..Nat Rev Cancer2003;3:721-32

[71] Milosevic M,Ménard C.Tumor hypoxia predicts biochemical failure following radiotherapy for clinically localized prostate cancer..Clin Cancer Res2012;18:2108-14

[72] Meijer TW,Span PN.Targeting hypoxia, HIF-1, and tumor glucose metabolism to improve radiotherapy efficacy..Clin Cancer Res2012;18:5585-94

[73] Horsman MR,Petersen JB.Imaging hypoxia to improve radiotherapy outcome..Nat Rev Clin Oncol2012;9:674-87

[74] Yang G,Qian X.Mesoporous silica nanorods intrinsically doped with photosensitizers as a multifunctional drug carrier for combination therapy of cancer..Nano Res2015;8:751-64

[75] Song G,Liang C.Catalase-loaded TaOx nanoshells as bio-nanoreactors combining high-z element and enzyme delivery for enhancing radiotherapy..Adv Mater2016;28:7143-8

[76] Zhang Y,Allen B.The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis..Nature1992;358:591-3

[77] Aebi H.Catalase in vitro..Methods Enzymol1984;105:121-6

[78] Caruso F,Möhwald H.Enzyme encapsulation in layer-by-layer engineered polymer multilayer capsules..Langmuir2000;16:1485-8

[79] Liu Y,Yan M.Biomimetic enzyme nanocomplexes and their use as antidotes and preventive measures for alcohol intoxication..Nat Nanotechnol2013;8:187-92 PMCID:PMC3670615

[80] Chen H,He W.H2O2-activatable and O2-evolving nanoparticles for highly efficient and selective photodynamic therapy against hypoxic tumor cells..J Am Chem Soc2015;137:1539-47

[81] Khau T,Schuliga M.Annexin-1 signals mitogen-stimulated breast tumor cell proliferation by activation of the formyl peptide receptors (FPRs) 1 and 2..FASEB J2011;25:483-96

[82] Snapkov I,Figenschau Y.The role of formyl peptide receptor 1 (FPR1) in neuroblastoma tumorigenesis..BMC Cancer2016;16:490 PMCID:PMC4950242

[83] Wong DY,Ang WH.Immuno-chemotherapeutic platinum(IV) prodrugs of cisplatin as multimodal anticancer agents..Angew Chem Int Ed Engl2014;53:6752-6

[84] Kim SD,Shim JW.A WKYMVm-containing combination elicits potent anti-tumor activity in heterotopic cancer animal model..PLoS One2012;7:e30522 PMCID:PMC3266298

[85] Gong G,Zhou Y.Molecular switch for the assembly of lipophilic drug incorporated plasma protein nanoparticles and in vivo image..Biomacromolecules2012;13:23-8

[86] Wang W,Zhao S.Human serum albumin (HSA) nanoparticles stabilized with intermolecular disulfide bonds..Chem Commun2013;49:2234-6

[87] Traverso N,Nitti M.Role of glutathione in cancer progression and chemoresistance..Oxid Med Cell Longev2013;2013:972913 PMCID:PMC3673338

[88] Chen Y,Jin H.Prodrug-like, PEGylated protein toxin trichosanthin for reversal of chemoresistance..Mol Pharm2017;14:1429-38

[89] Han EK,Tahir SK.Modulation of drug resistance by alpha-tubulin in paclitaxel-resistant human lung cancer cell lines..Eur J Cancer2000;36:1565-71

[90] Niazi M,Najafi Hajivar S.Nano-based strategies to overcome p-glycoprotein-mediated drug resistance..Expert Opin Drug Metab Toxicol2016;12:1021-33

[91] Ueda K,Morishima M.How does P-glycoprotein recognize its substrates?.Semin Cancer Biol1997;8:151-9

[92] Fang EF,Zhang L.Trichosanthin inhibits breast cancer cell proliferation in both cell lines and nude mice by promotion of apoptosis..PLoS One2012;7:e41592 PMCID:PMC3434199

[93] Shi WW,Shaw PC.Structural and functional investigation and pharmacological mechanism of trichosanthin, a type 1 ribosome-inactivating protein..Toxins (Basel)2018;10:335 PMCID:PMC6115768

[94] Liang J,Zhang M.Green synthesis of hyaluronic acid-based silver nanoparticles and their enhanced delivery to CD44+ cancer cells..RSC Adv2015;5:43733-40

[95] Kim M-H,Seol D-W.The secretable form of trimeric TRAIL, a potent inducer of apoptosis..Biochem Biophys Res Commun2004;321:930-5

[96] Walczak H,Ariail K.Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo..Nat Med1999;5:157-63

[97] Vrielink J,Setroikromo R.Synthetic constrained peptide selectively binds and antagonizes death receptor 5..FEBS J2010;277:1653-65

[98] Ivanov VN,Ronai Ze.Death receptors and melanoma resistance to apoptosis..Oncogene2003;22:3152-61

[99] Fan QL,Song LH.Synergistic antitumor activity of TRAIL combined with chemotherapeutic agents in A549 cell lines in vitro and in vivo..Cancer Chemother Pharmacol2005;55:189-96

[100] Wang S,Liu J.TRAIL and doxorubicin combination induces proapoptotic and antiangiogenic effects in soft tissue sarcoma in vivo..Clin Cancer Res2010;16:2591-604 PMCID:PMC2967255

[101] Singh TR,Chen X.Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo..Cancer Res2003;63:5390-400

[102] Orth M,Gerum S.Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches..Radiat Oncol2019;14:141 PMCID:PMC6688256

[103] Mackey JR,Selner M.Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines..Cancer Res1998;58:4349-57

[104] Damaraju VL,Young JD.Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy..Oncogene2003;22:7524-36

[105] Spratlin J,Glubrecht D.The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma..Clin Cancer Res2004;10:6956-61

[106] Vinay DS,Pawelec G.Immune evasion in cancer: Mechanistic basis and therapeutic strategies..Semin Cancer Biol2015;35:S185-98

[107] Cullis J,Avanzi A.Macropinocytosis of nab-paclitaxel drives macrophage activation in pancreatic cancer..Cancer Immunol Res2017;5:182-90 PMCID:PMC5570452

[108] Altieri DC.Survivin, cancer networks and pathway-directed drug discovery..Nat Rev Cancer2008;8:61-70

[109] Reichert S,Mirsch J.Survivin inhibition and DNA double-strand break repair: a molecular mechanism to overcome radioresistance in glioblastoma..Radiother Oncol2011;101:51-8

[110] Rödel F,Sprenger T.The role of survivin for radiation oncology: moving beyond apoptosis inhibition..Curr Med Chem2011;18:191-9

[111] Chanmee T,Konno K.Tumor-associated macrophages as major players in the tumor microenvironment..Cancers (Basel)2014;6:1670-90 PMCID:PMC4190561

[112] Hayashi N,Yano S.A novel photodynamic therapy targeting cancer cells and tumor-associated macrophages..Mol Cancer Ther2015;14:452-60

[113] Kang XJ,Peng HG.Codelivery of dihydroartemisinin and doxorubicin in mannosylated liposomes for drug-resistant colon cancer therapy..Acta Pharmacol Sin2017;38:885-96 PMCID:PMC5520183

[114] Condeelis J.Macrophages: obligate partners for tumor cell migration, invasion, and metastasis..Cell2006;124:263-6

[115] Mantovani A,Locati M.Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes..Trends Immunol2002;23:549-55

[116] Suzman DL.Castration-resistant prostate cancer: latest evidence and therapeutic implications..Ther Adv Med Oncol2014;6:167-79 PMCID:PMC4107711

[117] Meng Z,Wang R.NIR-laser-switched in vivo smart nanocapsules for synergic photothermal and chemotherapy of tumors..Adv Mater2016;28:245-53

[118] Chen W,Liu H.Black phosphorus nanosheet-based drug delivery system for synergistic photodynamic/photothermal/chemotherapy of cancer..Adv Mater2017;29:1603864

[119] Chen Q,Liu J.Intelligent albumin-MnO2 nanoparticles as pH-/H2 O2 -responsive dissociable nanocarriers to modulate tumor hypoxia for effective combination therapy..Adv Mater2016;28:7129-36

[120] Kolokythas G,Pouli N.Design, synthesis, and cytotoxic activity evaluation of new linear pyranoxanthone aminoderivatives..J Heterocycl Chem2011;48:927-35

[121] Wang QL,Li XD.An efficient direct competitive nano-ELISA for residual BSA determination in vaccines..Anal Bioanal Chem2017;409:4607-14

[122] Gough JE,Downes S.Cytotoxicity of glutaraldehyde crosslinked collagen/poly(vinyl alcohol) films is by the mechanism of apoptosis..J Biomed Mater Res2002;61:121-30

[123] White K,Guess WL.Toxicological studies of 2-mercaptoethanol..J Pharm Sci1973;62:237-41

[124] Gong G,Zhou Y.Molecular switch for the assembly of lipophilic drug incorporated plasma protein nanoparticles and in vivo image..Biomacromolecules2012;13:23-8

[125] Kuzu OF,Noory MA.Effect of lysosomotropic molecules on cellular homeostasis..Pharmacol Res2017;117:177-84

[126] Elzoghby AO,Hassanin IA.Lactoferrin, a multi-functional glycoprotein: active therapeutic, drug nanocarrier & targeting ligand..Biomaterials2020;263:120355 PMCID:PMC7480805

[127] Abdelmoneem MA,Zaky A.Dual-targeted casein micelles as green nanomedicine for synergistic phytotherapy of hepatocellular carcinoma..J Control Release2018;287:78-93